Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Apyx Medical (APYX) over the last 13 years, with Q3 2025 value amounting to $8.3 million.

  • Apyx Medical's Gains from Investment Securities rose 85.21% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 85.21%. This contributed to the annual value of $7.6 million for FY2024, which is 402.53% up from last year.
  • Apyx Medical's Gains from Investment Securities amounted to $8.3 million in Q3 2025, which was up 85.21% from $8.6 million recorded in Q2 2025.
  • In the past 5 years, Apyx Medical's Gains from Investment Securities ranged from a high of $8.6 million in Q2 2025 and a low of -$47000.0 during Q3 2021
  • For the 5-year period, Apyx Medical's Gains from Investment Securities averaged around $2.7 million, with its median value being $185500.0 (2024).
  • Per our database at Business Quant, Apyx Medical's Gains from Investment Securities plummeted by 32222.22% in 2024 and then surged by 3983701.5% in 2025.
  • Over the past 5 years, Apyx Medical's Gains from Investment Securities (Quarter) stood at -$47000.0 in 2021, then skyrocketed by 195.74% to $45000.0 in 2022, then surged by 4844.44% to $2.2 million in 2023, then crashed by 92.31% to $171000.0 in 2024, then soared by 4769.56% to $8.3 million in 2025.
  • Its Gains from Investment Securities was $8.3 million in Q3 2025, compared to $8.6 million in Q2 2025 and $7.9 million in Q1 2025.